Estimation of the delay for resumption of breastfeeding after 131-iodine therapy by milk radioactivity measurement.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Guidelines recommend stopping breastfeeding before radioactive iodine (131I) therapy, yet the optimal timing for safe resumption remains unclear. We report a detailed dosimetric case study of a 29-year-old woman treated with 3,700 MBq 131I for papillary thyroid carcinoma who wished to resume breastfeeding. Weekly breast milk samples were analyzed using calibrated gamma counting until radioactivity fell below a conservative safety threshold. Results showed substantial iodine excretion in milk (∼15% of administered activity) with biphasic clearance. Estimated infant radiation exposure varied dramatically depending on resumption timing, ranging from 0.62 to 688 mSv. A strict activity-based threshold suggested delaying breastfeeding for 51 days, whereas a dosimetric approach limiting infant exposure to 1 mSv supported resumption as early as 9-10 days post-therapy. These findings highlight the limitations of fixed recommendations and support an individualized, measurement-based strategy to optimize mother and child safety.